Elicio Therapeutics Inc. (NASDAQ: ELTX)
$4.57
+0.3200 ( +7.53% ) 39.2K
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.
Market Data
Open
$4.57
Previous close
$4.25
Volume
39.2K
Market cap
$49.22M
Day range
$4.08 - $4.58
52 week range
$2.96 - $11.45
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
10-q | Quarterly Reports | 86 | Nov 13, 2023 |
8-k | 8K-related | 19 | Nov 09, 2023 |
8-k | 8K-related | 14 | Nov 03, 2023 |
8-k | 8K-related | 21 | Oct 20, 2023 |
8-k | 8K-related | 12 | Oct 12, 2023 |
8-k | 8K-related | 40 | Sep 28, 2023 |
8-k | 8K-related | 14 | Sep 07, 2023 |
8-k | 8K-related | 12 | Aug 30, 2023 |
10-q | Quarterly Reports | 74 | Aug 14, 2023 |
8-k/a | 8K-related | 18 | Aug 14, 2023 |